Serotonin Plasma Membrane Transport Proteins
Research News and Information

Sunday, November 08, 2009

1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.

22 Sep 2009 Sequential structural modifications of the aryloxypropanamine template (e.g., atomoxetine, 2) led to a novel series of 1-(3-amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors (NRIs). ... Read more...

Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

14 Sep 2009 Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a polyglutamine expansion in the huntingtin protein (htt). Increasing evidence suggests that transglutaminase (TGase) plays a critical role in the ... Read more...

Autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen class II alleles in chronic fatigue syndrome: are they associated with age at onset and specific symptoms?

30 Aug 2009 This study aimed to determine the influence of autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen (HLA) class II genes on age at chronic fatigue syndrome (CFS) onset and symptoms. Eighty-one CFS patients were ... Read more...

Latest indexed articles for 'Serotonin Plasma Membrane Transport Proteins'

These are the very latest articles for this heading:

• 1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. 22 Sep 2009
• Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease. 14 Sep 2009
• The human serotonin transporter gene explains why some populations are more optimistic? 30 Aug 2009
• Autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen class II alleles in chronic fatigue syndrome: are they associated with age at onset and specific symptoms? 30 Aug 2009
• Candidate genes involved in neural plasticity and the risk for attention-deficit hyperactivity disorder: a meta-analysis of 8 common variants. 30 Aug 2009
• Genetic studies of drug response and side effects in the STAR*D study, part 2. 30 Aug 2009
• Vulnerability to depression: what is the role of stress genes in gene x environment interaction? 30 Aug 2009
• Impact of the tri-allelic serotonin transporter polymorphism on the white-matter tract connecting the amygdala and the prefrontal cortex. 24 Aug 2009
• In vivo characterization of a series of 18F-diaryl sulfides (18F-2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)phenylthio)benzenamine) for PET imaging of the serotonin transporter. 16 Aug 2009
• Drug-induced fibrotic valvular heart disease. 13 Aug 2009
• Serotonin transporter availability in the amygdala and bed nucleus of the stria terminalis predicts anxious temperament and brain glucose metabolic activity. 10 Aug 2009
• 5-HTTLPR modulates antidepressant efficacy in depressed women. 30 Jul 2009
• Genetic and environmental influence on attachment disorganization. 30 Jul 2009
• Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. 30 Jul 2009
• Allelic variation in the serotonin transporter promoter modulates cortical excitability. 30 Jul 2009
• Genetic studies of drug response and side effects in the STAR*D study, part 1. 30 Jul 2009
• The BDNF Val66Met polymorphism is associated with rumination in healthy adults. 30 Jul 2009
• Recent advances in the genetics of obsessive-compulsive disorder. 30 Jul 2009
• Sex influences the effect of a lifelong increase in serotonin transporter function on cerebral metabolism. 30 Jul 2009
• Corticotropin-releasing factor, serotonin, and sex: keys to the castle of depressive illness. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Serotonin Plasma Membrane Transport Proteins'

Definition: Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of serotonergic neurons. They are different than SEROTONIN RECEPTORS, which signal cellular responses to SEROTONIN. They remove SEROTONIN from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS. Regulates signal amplitude and duration at serotonergic synapses and is the site of action of the SEROTONIN UPTAKE INHIBITORS.

Registry Number: 0

Descriptor UI: D050486

Alternative terms: Serotonin Plasma Membrane Transport Proteins; 5HT Transporter; Neurotransmitter Transport Proteins, Serotonin-Specific; Neurotransmitter Transport Proteins, Serotonin Specific; Sodium-Dependent Serotonin Transporter; Serotonin Transporter, Sodium-Dependent; Sodium Dependent Serotonin Transporter; Transporter, Sodium-Dependent Serotonin; Serotonin Plasma Membrane Transporter Proteins; Serotonin Transporter; Transporter, Serotonin; SERT Proteins; 5-Hydroxytryptamine Plasma Membrane Transport Protein; 5 Hydroxytryptamine Plasma Membrane Transport Protein; Neurotransmitter Transporters, Serotonin-Specific; Neurotransmitter Transporters, Serotonin Specific; Serotonin-Specific Neurotransmitter Transporters; Transporters, Serotonin-Specific Neurotransmitter; Serotonectin; Serotonin Transporter, Platelets; Platelets Serotonin Transporter; Transporter, Platelets Serotonin; Platelet Serotonin Transporter; Serotonin Transporter, Platelet; Transporter, Platelet Serotonin;

Related Mesh Headings: Receptors, Serotonin;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.776.157.530.450.625.311; D12.776.157.530.562.374.875; D12.776.543.585.450.625.374; D12.776.543.585.562.374.875;

History Note: 2006(1992)